136 related articles for article (PubMed ID: 37797285)
1. Predictive Impact of
Moretto R; Germani MM; Ros J; Daniel F; Ghelardi F; Vetere G; Giordano M; Toledo RA; Bergamo F; Randon G; Elez E; Lonardi S; Pietrantonio F; Vignali P; Rossini D; Matito J; Ugolini C; Fontanini G; Masi G; Cremolini C
JCO Precis Oncol; 2023 Sep; 7():e2300255. PubMed ID: 37797285
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer.
Quintanilha JCF; Graf RP; Oxnard GR
Oncologist; 2023 Mar; 28(3):e171-e174. PubMed ID: 36779536
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with BRAF
Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
[TBL] [Abstract][Full Text] [Related]
4. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
[No Abstract] [Full Text] [Related]
5. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
6. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A
Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494
[TBL] [Abstract][Full Text] [Related]
7. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF
Elez E; Ros J; Fernández J; Villacampa G; Moreno-Cárdenas AB; Arenillas C; Bernatowicz K; Comas R; Li S; Kodack DP; Fasani R; Garcia A; Gonzalo-Ruiz J; Piris-Gimenez A; Nuciforo P; Kerr G; Intini R; Montagna A; Germani MM; Randon G; Vivancos A; Smits R; Graus D; Perez-Lopez R; Cremolini C; Lonardi S; Pietrantonio F; Dienstmann R; Tabernero J; Toledo RA
Nat Med; 2022 Oct; 28(10):2162-2170. PubMed ID: 36097219
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of radiotherapy combined with anti-angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer.
Zhai M; Zhang Z; Wang H; Ren J; Zhang S; Li M; Liu L; Li L; Zhang L; Li X; Zhang T; Lin Z
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38112050
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
Wu Q; Wang Z; Luo Y; Xie X
BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
Seeber A; Battaglin F; Zimmer K; Kocher F; Baca Y; Xiu J; Spizzo G; Novotny-Diermayr V; Rieder D; Puccini A; Swensen J; Ellis M; Goldberg RM; Grothey A; Shields AF; Marshall JL; Weinberg BA; Sackstein PE; Lim KH; Tan GS; Nabhan C; Korn WM; Amann A; Trajanoski Z; Berger MD; Lou E; Wolf D; Lenz HJ
Clin Cancer Res; 2022 May; 28(9):1863-1870. PubMed ID: 35254413
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
Colle R; Lonardi S; Cachanado M; Overman MJ; Elez E; Fakih M; Corti F; Jayachandran P; Svrcek M; Dardenne A; Cervantes B; Duval A; Cohen R; Pietrantonio F; André T
Oncologist; 2023 Sep; 28(9):771-779. PubMed ID: 37023721
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characteristics of
Huang ZY; Wen L; Ye LF; Lu YT; Pat Fong W; Zhang RJ; Wu SX; Chen ZG; Cai YY; Xu RH; Li YH; Du ZM; Wang DS
Ther Adv Med Oncol; 2024; 16():17588359231220600. PubMed ID: 38205077
[TBL] [Abstract][Full Text] [Related]
16. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
[TBL] [Abstract][Full Text] [Related]
17. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Fang X; Zhong C; Weng S; Hu H; Wang J; Xiao Q; Wang J; Sun L; Xu D; Liao X; Dong C; Zhang S; Li J; Ding K; Yuan Y
BMC Cancer; 2023 Jul; 23(1):676. PubMed ID: 37464378
[TBL] [Abstract][Full Text] [Related]
18. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Moretto R; Elliott A; Rossini D; Intini R; Conca V; Pietrantonio F; Sartore-Bianchi A; Antoniotti C; Rasola C; Scartozzi M; Salati M; Pella N; Calegari MA; Carullo M; Corti F; Mauri G; Fassan M; Masi G; Brodskiy P; Lenz HJ; Shields A; Lonardi S; Korn M; Cremolini C
Br J Cancer; 2022 Sep; 127(5):957-967. PubMed ID: 35665778
[TBL] [Abstract][Full Text] [Related]
19. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
[TBL] [Abstract][Full Text] [Related]
20. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
